Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBT (2016 - 2026)

Anika Therapeutics has reported EBT over the past 17 years, most recently at -$4.8 million for Q1 2026.

  • Quarterly EBT fell 24.61% to -$4.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$12000.0 through Mar 2026, up 99.8% year-over-year, with the annual reading at $940000.0 for FY2025, 123.05% up from the prior year.
  • EBT was -$4.8 million for Q1 2026 at Anika Therapeutics, down from $11.0 million in the prior quarter.
  • Over five years, EBT peaked at $25.3 million in Q4 2023 and troughed at -$12.0 million in Q1 2023.
  • The 5-year median for EBT is -$3.1 million (2023), against an average of -$262882.4.
  • The largest YoY upside for EBT was 963.61% in 2025 against a maximum downside of 788.0% in 2025.
  • A 5-year view of EBT shows it stood at $12.7 million in 2022, then skyrocketed by 99.22% to $25.3 million in 2023, then crashed by 105.04% to -$1.3 million in 2024, then skyrocketed by 963.61% to $11.0 million in 2025, then tumbled by 143.78% to -$4.8 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's EBT are -$4.8 million (Q1 2026), $11.0 million (Q4 2025), and -$2.2 million (Q3 2025).